This article is intended for research and educational purposes only. LL-37 is a Research Use Only (RUO) compound supplied for laboratory investigation. It is not approved for human use, is not a medicine, and must not be administered to humans or animals outside of licenced research settings.
Introduction: Why LL-37 Is a Significant Research Target in Oral Biology
LL-37 — the sole human cathelicidin, derived from the C-terminal cleavage of hCAP18 (human cationic antimicrobial protein 18) by serine proteases — is one of the most abundant antimicrobial peptides in oral mucosal biology. Gingival epithelial cells, salivary glands, neutrophils, and oral keratinocytes all constitutively and inducibly produce LL-37, making it a frontline component of innate mucosal immunity in the oral cavity. Its research significance spans direct bacterial killing (particularly periodontal pathogens), biofilm disruption, immunomodulation at the gingival interface, epithelial wound healing, and interactions with the oral microbiome that extend beyond simple antimicrobial activity.
This post covers LL-37 oral biology as a distinct research angle — focused on periodontal pathogen biology, oral biofilm research, gingival epithelial signalling, salivary LL-37 as a diagnostic biomarker, and the contextual complexity of LL-37’s dual role as both antimicrobial agent and potential pro-inflammatory mediator at high concentrations in oral tissues.
🔗 Related Reading: For a comprehensive overview of LL-37 research, mechanisms, UK sourcing, and safety data, see our LL-37 Pillar Guide.
LL-37 Expression in Oral Tissues: Constitutive and Inducible Sources
Salivary LL-37 originates from multiple cell types: parotid and submandibular gland acinar cells secrete hCAP18 into saliva (detectable by ELISA and western blot in whole unstimulated saliva and parotid secretions), oral keratinocytes constitutively express hCAP18 mRNA as demonstrated by RT-PCR in oral epithelial biopsies, and neutrophils — the primary source of systemic LL-37 — transmigrate through the junctional epithelium in large numbers (estimated 30,000 per minute in healthy gingival crevicular fluid) delivering their secretory granule-stored hCAP18 into the gingival crevice.
Gingival crevicular fluid (GCF) LL-37 concentrations are measurable by ELISA (Hycult Biotech or R&D Systems competitive ELISA; standard sampling by periopaper strips for 30 seconds at standardised sites) and are elevated in periodontitis compared to periodontally healthy controls, reflecting increased neutrophil transmigration and epithelial induction. Salivary LL-37 concentration differs from GCF LL-37 — whole saliva represents a diluted mixed secretion, while GCF provides site-specific periodontal sulcus LL-37 concentrations more relevant to periodontal pathogen interactions.
VDR (vitamin D receptor) and 1,25(OH)₂D₃ (calcitriol) are the primary inducers of hCAP18/LL-37 expression in oral keratinocytes — a transcriptional pathway involving VDRE (vitamin D response element) in the hCAP18 promoter. This VDR-LL-37 axis is researchable using 1,25(OH)₂D₃ dose-response transcription assays (0.1–100nM calcitriol for 24–72h in primary human gingival keratinocytes; OKF6-TERT2 oral keratinocyte line), qPCR for hCAP18 mRNA, and western blot for hCAP18 protein and processed LL-37 (detected by anti-LL-37 antibody after proteinase K/trypsin processing to confirm cleavage from hCAP18).
Periodontal Pathogen Biology: Key Targets for LL-37 Research
The periodontal microbiome is dominated by a “red complex” of keystone pathogens — Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia — together with accessory pathogens including Fusobacterium nucleatum, Prevotella intermedia, and Aggregatibacter actinomycetemcomitans (Aa). LL-37 research in the periodontal context centres on its antimicrobial and biofilm-disrupting activity against these species.
Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) determination for LL-37 against periodontal pathogens uses broth microdilution (CLSI M07-A9) under anaerobic conditions (80% N₂, 10% CO₂, 10% H₂) in pre-reduced brain heart infusion (BHI) medium supplemented with hemin (5µg/mL) and menadione (1µg/mL) for P. gingivalis. Typical LL-37 MIC values against P. gingivalis range 2–8µg/mL, against F. nucleatum 1–4µg/mL, with T. denticola often more resistant (MIC 8–32µg/mL). These values are condition-dependent — pH, salt concentration, presence of saliva proteins and mucins, and protease activity all affect LL-37 antimicrobial potency in vitro.
P. gingivalis is notable for expressing multiple LL-37-resistance mechanisms: gingipain proteases (RgpA, RgpB, Kgp) degrade LL-37 rapidly, LPS deacylation reduces the electrostatic interaction with LL-37, and outer membrane vesicle (OMV) shedding sequesters LL-37 before membrane contact. Research quantifying P. gingivalis LL-37 resistance uses: protease-dead gingipain mutants (Δkgp, Δrgp) to confirm gingipain contribution to LL-37 degradation (tricine SDS-PAGE of incubated mixtures), LPS chemotype analysis (MALDI-TOF lipid A profiling), and OMV sedimentation (120,000g ultracentrifugation) to characterise each resistance mechanism independently.
Oral Biofilm and Dental Plaque Research
Dental plaque is a structurally complex, multi-species biofilm attached to the tooth surface and extending into the periodontal sulcus. Anti-biofilm activity of LL-37 is mechanistically distinct from its planktonic antimicrobial activity: biofilm-mode bacteria are 10–1,000-fold more tolerant of antimicrobial peptides due to matrix-mediated sequestration (eDNA, extracellular polysaccharides, and proteins binding LL-37), altered membrane composition in biofilm-mode cells, and slow-growing persister cell subpopulations.
Oral biofilm research models range from simple single-species biofilms (P. gingivalis on saliva-coated hydroxyapatite [sHA] discs or glass coverslips) to complex multi-species systems: the Zürich biofilm model (10 species, 64.5h sequential inoculation under flow conditions), the CDFF (Constant-Depth Film Fermenter) model, and in vitro subgingival plaque models inoculated with GCF-derived or plaque-derived polymicrobial communities. CLSM (confocal laser scanning microscopy) with LIVE/DEAD BacLight (SYTO9 green/propidium iodide red) quantifies biofilm viability spatially; crystal violet staining measures total biofilm biomass; and qPCR of 16S rRNA species-specific primers quantifies individual species contribution within polymicrobial biofilms.
LL-37 anti-biofilm mechanisms include: eDNA degradation (LL-37 binds and destabilises eDNA matrix through charge interaction; quantified by PicoGreen DNA fluorometry in biofilm supernatant after treatment); direct membrane disruption of biofilm cells at contact points (ToF-SIMS chemical imaging, cryo-EM biofilm cross-sections); and QSI (quorum sensing inhibition) — LL-37 disrupts P. gingivalis LuxS/AI-2 quorum sensing at sub-MIC concentrations, reducing biofilm formation rather than killing established biofilm.
Gingival Epithelial Signalling: EGFR, FPRL1, and Wound Healing
Beyond its antimicrobial action, LL-37 activates receptors on gingival epithelial cells that coordinate wound healing and innate immune responses. The primary signalling receptors include: FPRL1 (formyl peptide receptor-like 1; now designated FPR2/ALX) — a G-protein coupled receptor coupled to Gi-βγ-PI3K-Akt-Rac1-lamellipodia in epithelial cells that promotes migration; and EGFR — activated through metalloprotease (ADAM10/17)-mediated HB-EGF ectodomain shedding triggered by LL-37-FPRL1 signalling, leading to Ras-MEK-ERK1/2 proliferative signalling.
In primary human gingival fibroblasts (HGFF) and gingival keratinocytes (OKF6-TERT2), LL-37 at 1–5µg/mL promotes scratch wound closure (scratch wound assay in monolayer culture, Fiji wound area quantification over 12–24h time-lapse), increases Ki-67+ and BrdU+ proliferation indices, and upregulates migration markers (paxillin, vinculin focal adhesion distribution by confocal IF). The EGFR transactivation mechanism is confirmed by: AG1478 (EGFR kinase inhibitor) abolition of LL-37-induced ERK1/2 phosphorylation; GM6001 (pan-ADAM metalloprotease inhibitor) reduction of EGFR activation; and HB-EGF ELISA in conditioned media 15–30 minutes after LL-37 treatment confirming ectodomain shedding.
Concentration-dependence is critical for gingival LL-37 research: concentrations <1–2µg/mL typically promote wound healing and immunomodulation, while concentrations >5–10µg/mL produce cytotoxicity (LDH release, propidium iodide uptake by flow cytometry) through membrane disruption. GCF LL-37 concentrations in periodontitis (reported up to 15–40µg/mL at inflamed sites) thus occupy a potentially pro-inflammatory/cytotoxic range, which contextualises the bidirectional biology of LL-37 at diseased versus healthy gingival sites.
Immunomodulation at the Gingival Interface: NF-κB, TLR Modulation, and Cytokine Biology
The periodontal immune environment is dominated by TLR2 and TLR4 signalling (recognising lipoproteins/PGN and LPS from oral bacteria), NOD1/NOD2 (muramyl dipeptide sensing), and NLRP3 inflammasome activation (by uric acid crystals, ATP, and bacterial components). LL-37 modulates this inflammatory milieu through several mechanisms: direct TLR4 LPS-binding (LL-37 binds LPS and prevents TLR4 engagement — detectable by LAL assay LPS neutralisation and ELISA TNF-α/IL-8 reduction in THP-1 monocytes); and intracellular STING (cGAS-STING DNA-sensing) pathway activation by LL-37-complexed self-DNA (IFN-β, CXCL10 induction — an immunostimulatory mode relevant to gingival interferonopathy research).
In primary human gingival fibroblasts stimulated with P. gingivalis LPS (1–10µg/mL), LL-37 co-treatment reduces NF-κB p65 nuclear translocation (confocal immunofluorescence DAPI/p65 overlap), IL-6 and IL-8 secretion (ELISA or Luminex multiplex), and ICAM-1 surface expression (flow cytometry). These anti-inflammatory effects at sub-cytotoxic concentrations (1–2µg/mL) contrast with the pro-inflammatory cytokine induction (IL-1β, TNF-α, IL-6) produced by LL-37 at higher concentrations (10–20µg/mL) through FPRL1-mediated Ca²⁺ signalling and NLRP3 inflammasome priming.
P. gingivalis gingipain-mediated LL-37 degradation fragments retain biological activity: the peptide fragment GL-13 (13 C-terminal amino acids of LL-37) retains antimicrobial activity against P. gingivalis with reduced cytotoxicity, making it a research comparator for dissociating antimicrobial from cytotoxic LL-37 biology. Mass spectrometry (MALDI-TOF or LC-MS/MS) of LL-37 incubated with recombinant gingipains or with P. gingivalis culture supernatant identifies the degradation fragment profile and assesses which fragments retain specific biological activities.
Salivary LL-37 as a Periodontal Biomarker
Saliva-based biomarker research for periodontal disease is a growing field, driven by the non-invasive sampling advantages of saliva over GCF or tissue biopsy. LL-37 concentrations in whole unstimulated saliva (WUS) are measurable by sandwich ELISA (detection limit ~0.1ng/mL), and meta-analyses of published data suggest elevated salivary LL-37 in periodontitis versus periodontally healthy subjects, though with substantial intra-study variability driven by sampling standardisation (fasting duration, time of day, collection method) and comorbidity differences (diabetes, smoking — both reduce salivary LL-37).
Research designs for salivary LL-37 biomarker studies use: cross-sectional case-control (periodontitis vs healthy), longitudinal (before and after full-mouth scaling and root planing, SRP), and intervention designs (VDR agonist supplementation impact on salivary LL-37). Clinical periodontal parameters recorded in parallel include: full-mouth plaque score (FMPS), full-mouth bleeding score (FMBS), probing pocket depth (PPD mm at 6 sites per tooth), clinical attachment level (CAL), bleeding on probing (BOP), and radiographic bone loss (periapical radiograph or CBCT for standardised alveolar crest height measurement).
ROC (receiver operating characteristic) analysis of salivary LL-37 against clinical periodontitis diagnosis produces AUC values typically in the 0.65–0.80 range in published studies — moderate diagnostic accuracy that suggests utility as a panel biomarker alongside IL-1β, MMP-8 (collagenase-2 from neutrophils), and RANKL:OPG ratio rather than as a standalone diagnostic. Salivary proteomics (nano-LC-MS/MS iTRAQ-based quantification) provides an unbiased approach to identifying LL-37 alongside other AMP candidates (defensins: HBD-1, HBD-2, HBD-3; statherin; histatins) in a biomarker discovery framework.
Oral Microbiome Research: LL-37 Shaping of Community Composition
LL-37 acts as a selective pressure on the oral microbiome — more potently killing some species than others, thereby shaping community composition. Commensal streptococci (Streptococcus gordonii, S. sanguinis, S. mitis) are generally more LL-37-resistant than periodontal pathogens (with some exceptions for highly resistant P. gingivalis gingipain+ strains), meaning that LL-37 may normally maintain a commensal-dominant microbiome by preferentially suppressing pathogenic species.
Oral microbiome composition is characterised by 16S rRNA V3-V4 amplicon sequencing (Illumina MiSeq 2×300bp; SILVA database taxonomy) or full-length 16S by nanopore (Oxford Nanopore Technologies; MinION flow cell) in saliva, supragingival plaque, and subgingival plaque samples (separately collected by curette for subgingival sites). Alpha diversity (Shannon H, Chao1, Simpson) and beta diversity (Bray-Curtis dissimilarity PERMANOVA; UniFrac weighted/unweighted) are the primary microbiome community structure endpoints. Differential abundance analysis (DESeq2, LEfSe) identifies taxa that differ between LL-37-high and LL-37-low subjects.
In vitro microbiome perturbation experiments use saliva-derived mixed communities stabilised in CDFF or batch fermentation (Sheldon BioFermentor), with LL-37 added at physiologically relevant concentrations (1–10µg/mL) for 24–72h, followed by 16S sequencing of surviving communities. This provides mechanistic evidence for LL-37’s selective antimicrobial pressure on microbiome composition distinct from correlational clinical studies.
Peri-Implant Biology: LL-37 at the Implant-Tissue Interface
Dental implants lack the junctional epithelium and dento-gingival complex found around natural teeth, making the peri-implant sulcus more vulnerable to dysbiotic biofilm formation. The peri-implant microbiome partially overlaps with the periodontal microbiome, with P. gingivalis, F. nucleatum, and Aa implicated in peri-implantitis (inflammatory bone loss around implants). LL-37 research at the implant-tissue interface examines: titanium surface LL-37 coating for anti-biofilm activity, peri-implant crevicular fluid (PICF) LL-37 concentrations versus GCF, and gingival keratinocyte LL-37 expression at the peri-implant mucosa (reduced junctional epithelium differentiation means potentially altered hCAP18 expression).
Titanium surface LL-37 functionalisation uses: direct physical adsorption (LL-37 in PBS incubated with sand-blasted acid-etched [SLA] titanium discs 24h, then rinsed; quantified by Micro BCA assay for surface-bound protein), covalent silanisation coupling (aminosilane/glutaraldehyde linker), and layer-by-layer polyelectrolyte coating (chitosan/LL-37 multilayer deposition). Anti-biofilm efficacy is assessed by P. gingivalis and F. nucleatum biofilm formation on functionalised vs unfunctionalised titanium discs (24–48h anaerobic; CLSM LIVE/DEAD; crystal violet biomass; qPCR species quantification) and by LL-37 release kinetics (ELISA of incubation medium at 1h, 6h, 24h, 72h).
LL-37 and Oral Wound Healing: Extraction Socket and Mucosal Ulcer Research
Post-extraction wound healing and oral mucosal ulcer resolution involve coordinated inflammation, re-epithelialisation, and connective tissue remodelling processes in which LL-37 has mechanistic roles. Extraction socket research models use the rat maxillary first molar extraction model (standardised extraction at day 0, assessment at days 3, 7, 14, 21) with endpoints including: H&E histomorphometry of socket fill (bone vs connective tissue vs epithelium area%), TRAP-5b IHC for osteoclasts in residual socket walls, COL1A1 Masson trichrome collagen deposition, and CD31/PECAM-1 microvessel density for angiogenesis quantification. Local LL-37 application (gelatin scaffold-loaded; collagen sponge-delivered; hydrogel formulation) at the time of extraction allows restorative biology research.
Oral mucosal ulcer models use acetic acid (50µL, 50% v/v applied to lateral tongue for 60s under isoflurane) or SDS (2.5% sodium dodecyl sulphate mucosal application) in rats or hamsters, producing standardised shallow ulcers with 7–14 day healing trajectories. Ulcer area (digital photography/ImageJ measurement), histological re-epithelialisation score, and pain surrogate endpoints (mechanical von Frey filament threshold at ulcer margin) are the primary readouts. LL-37 applied in carboxymethylcellulose (CMC) gel vehicle to ulcer surfaces post-induction tests healing-promoting vs potentially cytotoxic effects at the concentration used (1–10µg/mL).
Experimental Design Considerations for Oral LL-37 Research
Oral biology LL-37 research faces several design challenges: salivary protease activity (cathepsins, matrix metalloproteinases, gingipains in periodontitis samples) rapidly degrades exogenously applied LL-37, necessitating protease inhibitor cocktails (Complete Mini EDTA-free; Roche) in ex vivo experiments and protease-stable analogues (WLBU2; D-amino acid variants) for in vivo oral delivery. The cation sensitivity of LL-37 — where physiological NaCl (150mM) and Ca²⁺/Mg²⁺ reduce antimicrobial potency by charge shielding — means that in vitro antimicrobial assays in nutrient-rich media may substantially underestimate in vivo potency at mucosal surfaces where ionic strength is lower.
Positive controls for oral LL-37 experiments include: chlorhexidine digluconate (0.2% CHX — clinical standard for plaque control), human β-defensin-2 (HBD-2, same epithelial AMP category as LL-37), and truncated LL-37 fragments (LL-13, FK-13, KR-12) for structure-activity relationship comparisons. Negative controls must include scrambled peptide (same amino acid composition, random sequence) to distinguish sequence-specific from physicochemical (charge/amphipathicity) LL-37 effects.
🔗 Related Reading: For LL-37 biology in a broader antimicrobial peptide research context, see our LL-37 Pillar Guide.
Summary of Key Research Endpoints for LL-37 Oral Research
Core oral LL-37 research endpoints include: GCF LL-37 ELISA (periopaper sampling), whole unstimulated saliva LL-37 ELISA, PPD/CAL/FMBS/FMBS periodontal clinical parameters, P. gingivalis/F. nucleatum/T. denticola MIC/MBC (anaerobic broth microdilution), oral biofilm CLSM LIVE/DEAD/crystal violet biomass/qPCR 16S species quantification, eDNA PicoGreen quantification, scratch wound closure Fiji time-lapse, EGFR Tyr-1068/ERK1/2/Akt Ser-473 western blot, FPRL1 Ca²⁺ HTRF/FLIPR assay, NF-κB p65 nuclear confocal, IL-6/IL-8/IL-1β/TNF-α Luminex, VCAM-1/ICAM-1 flow, 16S V3-V4 microbiome alpha/beta diversity Shannon-Chao1-Bray-Curtis, LDH cytotoxicity at >5µg/mL, hCAP18 mRNA qPCR VDR-1,25(OH)₂D₃ 0.1-100nM induction, and titanium surface LL-37 adsorption Micro BCA ELISA with biofilm anti-adhesion CLSM.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified LL-37 for research and laboratory use. View UK stock →
